Anthony Marquez: Right. And my second question is, I think part of the reason why the stock trades were traded, there’s no analyst coverage at all. I don’t know if — and as we all know, you’ve got to pay something in this environment or in the micro cap sector you have to pay, in essence, you have to — although everybody will deny it, you have to basically pay something for research coverage. Has there been any movement to try and get some research — even some of the paid research services, which I believe are pretty good, would be better than nothing because at least you get your name out there. I’m just curious, has that been — I’m not sure has there been any effort made to try and attract some type of analyst coverage.
Raymond Stachowiak: I think those efforts are starting to be made. And I will just comment that I’m kind of an old school investor in the sense that before I start promoting an investment, let’s demonstrate a good solid foundation, sustained growth, sustained profitability, something to lean on, something to sell, something to go to pitch to the financial analysts community.
Anthony Marquez: I’m going to differ a little bit with you in that respect, and that is that you’ve just laid out in the prior call, you just laid out a good reason forgetting about any growth. Just the way we are today would be a great reason to buy the stock and people buy stocks for different reasons. Some stocks are growth stocks, some stocks are asset plays. And I think in this situation, you have an asset play right now, coupled with a potential growth — with a potential growth play. So I’m going to disagree a little bit by saying why try and get analyst research now because you haven’t shown sustained growth. But what you have shown is the ability to continue to generate impressive EBITDA relative to your market cap.
So I’ll just leave it at that. I’m not trying to be argumentative, I’m just pointing out that I think it’s a mistake not to try and get analyst coverage because I think you fall into many buckets and the bucket right now is clearly an asset play. Anyway, thank you very much I appreciate you taking the questions.
Raymond Stachowiak: Tony, let me digest all that and reflect on it. I think those are really — it’s really great feedback. And I’d like to think of myself as someone that listens well, okay, and always open to input. So let me take that under advice, , okay?
Anthony Marquez: All right. Thank you.
Raymond Stachowiak: All right.
Operator: Thank you. And the next question comes from Tony Kamin with Eastwood Partners.
Tony Kamin: Hi, everyone. It was really nice to hear the sort of comprehensive plan you have now in terms of both working more closely with manufacturers and also the new efforts to reach out to end customers. So great to hear that. It just sounds very comprehensive. And I guess my first question is around the new customer that you announced with the $1.3 million sale. Can you kind of characterize that customer? Is it a hospital? Or is it some other kind of entity? Or — and is it Gamma Knife equipment, or is it something other than that?
Raymond Stachowiak: Yes. I think I will divert that question to Peter. However, we probably cannot identify that customer by name because of our nondisclosure agreements that we have sometimes with our clients. But
Tony Kamin: That’s why I characterize rather than name.
Raymond Stachowiak: Yes, Peter, could you characterize that client?